Sage Therapeutics Q2 2025: ZURZUVAE rev $23.2M (+68% QoQ); net loss $49.7M; Supernus acquisition on track

Sage Therapeutics, Inc.

2025-Q2 EPS reported -$1.80 revenue$45,724,000

ZURZUVAE collaboration revenue of $23.2M (50% of Biogen net sales), up 68% from Q1 2025.
Net loss narrowed to $49.7M from $102.9M in Q2 2024; cash and equivalents of $366M.
Acquisition by Supernus for $8.50/share cash plus CVR up to $3.50/share, expected to close Q3 2025.
Phase 1 data for SAGE-319 expected late 2025; ongoing pipeline reprioritization.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.